← Back to Screener
Xencor, Inc. (XNCR)
Price$12.80
Favorite Metrics
Price vs S&P 500 (26W)-8.52%
Price vs S&P 500 (4W)-1.83%
Market Capitalization$941.60M
All Metrics
Book Value / Share (Quarterly)$8.84
P/TBV (Annual)1.74x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-8.63%
Cash Flow / Share (Quarterly)$-1.92
Price vs S&P 500 (YTD)-18.83%
Net Profit Margin (TTM)-73.20%
EPS (TTM)$-1.24
10-Day Avg Trading Volume0.79M
EPS Excl Extra (TTM)$-1.24
Revenue Growth (5Y)0.46%
EPS (Annual)$-1.24
ROI (Annual)-12.17%
Net Profit Margin (5Y Avg)-73.27%
Cash / Share (Quarterly)$7.62
Revenue Growth QoQ (YoY)-59.67%
ROA (Last FY)-10.50%
Revenue Growth TTM (YoY)13.65%
EBITD / Share (TTM)$-2.37
ROE (5Y Avg)-13.05%
Operating Margin (TTM)-148.65%
Cash Flow / Share (Annual)$-1.92
P/B Ratio1.48x
P/B Ratio (Quarterly)1.72x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)8.02x
Net Interest Coverage (TTM)-5.50x
ROA (TTM)-10.42%
EV / EBITDA (TTM)16.93x
EPS Incl Extra (Annual)$-1.24
Current Ratio (Annual)6.25x
Quick Ratio (Quarterly)6.02x
3-Month Avg Trading Volume0.79M
52-Week Price Return37.18%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.73
P/S Ratio (Annual)7.50x
Asset Turnover (Annual)0.14x
52-Week High$18.69
Operating Margin (5Y Avg)-88.36%
EPS Excl Extra (Annual)$-1.24
CapEx CAGR (5Y)-25.55%
Tangible BV CAGR (5Y)2.42%
26-Week Price Return0.23%
Quick Ratio (Annual)6.02x
13-Week Price Return-9.62%
Total Debt / Equity (Annual)0.19x
Current Ratio (Quarterly)6.25x
Enterprise Value$1,007.274
Revenue / Share Growth (5Y)-4.64%
Asset Turnover (TTM)0.14x
Book Value / Share Growth (5Y)-2.20%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-71.38%
Cash / Share (Annual)$7.62
3-Month Return Std Dev63.85%
Net Income / Employee (TTM)$-0
ROE (Last FY)-14.46%
Net Interest Coverage (Annual)-1.77x
EPS Basic Excl Extra (Annual)$-1.24
P/FCF (TTM)5.25x
Receivables Turnover (TTM)2.79x
Total Debt / Equity (Quarterly)0.19x
EPS Incl Extra (TTM)$-1.24
Receivables Turnover (Annual)2.79x
ROI (TTM)-11.96%
P/S Ratio (TTM)7.50x
Pretax Margin (5Y Avg)-71.63%
Revenue / Share (Annual)$1.69
Tangible BV / Share (Annual)$8.73
Price vs S&P 500 (52W)2.09%
Year-to-Date Return-14.70%
5-Day Price Return8.20%
EPS Normalized (Annual)$-1.24
ROA (5Y Avg)-9.08%
Net Profit Margin (Annual)-73.20%
Month-to-Date Return8.29%
Cash Flow / Share (TTM)$-1.81
EBITD / Share (Annual)$-2.37
Operating Margin (Annual)-148.65%
LT Debt / Equity (Annual)0.12x
ROI (5Y Avg)-10.36%
LT Debt / Equity (Quarterly)0.12x
EPS Basic Excl Extra (TTM)$-1.24
P/TBV (Quarterly)1.74x
P/B Ratio (Annual)1.72x
Pretax Margin (TTM)-71.38%
Book Value / Share (Annual)$8.84
Price vs S&P 500 (13W)-12.48%
Beta1.02x
P/FCF (Annual)17.66x
Revenue / Share (TTM)$1.68
ROE (TTM)-14.58%
52-Week Low$6.92
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.15
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
XNCRXencor, Inc. | 7.50x | 13.65% | — | — | $12.80 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Xencor Inc is a clinical-stage biopharmaceutical company developing engineered antibody therapeutics for cancer and autoimmune diseases. The company leverages its proprietary XmAb technology platform to advance a pipeline of antibody candidates through clinical development. Xencor generates revenue through collaboration and licensing agreements with larger pharmaceutical partners, reducing development risk while advancing its research programs.